Predicting risk of cancer during HIV infection: The role of inflammatory and coagulation biomarkers

Álvaro H. Borges, Michael J. Silverberg, Deborah Wentworth, Andrew E. Grulich, Gerd Fätkenheuer, Ronald Mitsuyasu, Giuseppe Tambussi, Caroline A. Sabin, James D. Neaton, Jens D. Lundgren

Research output: Contribution to journalArticlepeer-review


Objective: To investigate the relationship between inflammatory [interleukin-6 (IL-6) and C-reactive protein (CRP)] and coagulation (D-dimer) biomarkers and cancer risk during HIV infection. Design: A prospective cohort. Methods: HIV-infected patients on continuous antiretroviral therapy (ART) in the control arms of three randomized trials (N = 5023) were included in an analysis of predictors of cancer (any type, infection-related or infection-unrelated). Hazard ratios for IL-6, CRP and D-dimer levels (log2-transformed) were calculated using Cox models stratified by trial and adjusted for demographics and CD4+ cell counts and adjusted also for all biomarkers simultaneously. To assess the possibility that biomarker levels were elevated at entry due to undiagnosed cancer, analyses were repeated excluding early cancer events (i.e. diagnosed during first 2 years of follow-up). Results: During approximately 24 000 person-years of follow-up (PYFU), 172 patients developed cancer (70 infection-related; 102 infection-unrelated). The risk of developing cancer was associated with higher levels (per doubling) of IL-6 (hazard ratio 1.38, P

Original languageEnglish
Pages (from-to)1433-1441
Number of pages9
JournalAIDS (London, England)
Issue number9
Publication statusPublished - Jun 1 2013


  • Biomarkers
  • C-reactive protein
  • Cancer
  • D-dimer
  • HIV
  • Interleukin-6

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases


Dive into the research topics of 'Predicting risk of cancer during HIV infection: The role of inflammatory and coagulation biomarkers'. Together they form a unique fingerprint.

Cite this